IVIM Technology, Inc (460470) Fair Value & Analysis
Healthcare · KR · Market cap 42.5B KRW
Fair value as of: Jul 21, 2026
From 1 valuation models · updated 20 days ago
Fair value updated Jul 21, 2026, revised from 1,198 KRW to 1,197 KRW (−0.1%) since Jul 11, 2026. Share price +8.0% over the past month.
Below-average quality, and screening another 62% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,496 KRW). The favourable scenario is already priced in.
- Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (789.71 KRW to 1,496 KRW) leaves room in how you read the outcome.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
24‑month range 2,530 KRW – 13,360 KRW · fair‑value band 789.71 KRW – 1,496 KRW · the 3,180 KRW price screens above the 1,197 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.
Analysis
IVIM Technology, Inc (460470) currently trades at 3,180 KRW, while our model-based Fair Value estimate is 1,197 KRW, implying the stock looks roughly 62.4% overvalued today. The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, IVIM Technology, Inc generated revenue of 4.3B KRW at a net margin of -87.3%. Revenue declined 48.9% year over year. It earns a return on equity of -13.4%. Net debt stands at 507M KRW. Fundamentals as of Jul 21, 2026
Our scenario range runs from 789.71 KRW (bear case) to 1,496 KRW (bull case); at 3,180 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 36% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -62%, 460470 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 460470 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
IVIM Technology, Inc. develops intravital microscopy (IVM) platform. Its products include IVM-C3, a system for simultaneously observing various multi-cellular behaviors in small live animal models; IVM-M3, a system for users who need to conduct deeper-tissue imaging using less-scattering NIR wavelength; IVM-CMS3 for intravital functional imaging; IVM-CM3 …
Full company description
IVIM Technology, Inc. develops intravital microscopy (IVM) platform. Its products include IVM-C3, a system for simultaneously observing various multi-cellular behaviors in small live animal models; IVM-M3, a system for users who need to conduct deeper-tissue imaging using less-scattering NIR wavelength; IVM-CMS3 for intravital functional imaging; IVM-CM3 that provides three-dimensional imaging of living cells near the skin or deep into the tumor in small animals; IVM-MS3 for in vivo imaging; and IVM-customized products. The company also provides preclinical contract research organization services. Its products are used in live cell intravital imaging, repetitive intravital imaging, in vivo drug efficacy monitoring, in vivo drug delivery monitoring, and ex vivo imaging applications. The company was founded in 2017 and is based in Daejeon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
IVIM Technology, Inc reported revenue of 4.4B KRW in FY2025 versus 527M KRW in FY2021, a compound +69.8%/yr. Reported net income was −3.8B KRW in FY2025.
460470 screens 62% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare IVIM Technology, Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is IVIM Technology, Inc (460470) overvalued or undervalued?
What is the fair value of 460470?
What is the quality score of 460470?
What is the revenue of IVIM Technology, Inc (460470)?
What is the net profit margin of 460470?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track IVIM Technology, Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.